scholarly journals Effects of Odanacatib on the Radius and Tibia of Postmenopausal Women: Improvements in Bone Geometry, Microarchitecture, and Estimated Bone Strength

2014 ◽  
Vol 29 (8) ◽  
pp. 1786-1794 ◽  
Author(s):  
Angela M Cheung ◽  
Sharmila Majumdar ◽  
Kim Brixen ◽  
Roland Chapurlat ◽  
Thomas Fuerst ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Bone Strength ◽  
Bone Geometry

Alendronate Increases Bone Density and Bone Strength at the Distal Radius in Postmenopausal Women

1999 ◽  
Vol 14 (8) ◽  
pp. 1387-1393 ◽  
Author(s):  
Peter F. Schneider ◽  
Manfred Fischer ◽  
Bruno Allolio ◽  
Dieter Felsenberg ◽  
Ulf Schröder ◽  
...  
Keyword(s):  
Bone Density ◽  
Postmenopausal Women ◽  
Bone Strength ◽  
Distal Radius

Effect of Rheumatoid Arthritis on Volumetric Bone Mineral Density and Bone Geometry, Assessed by Peripheral Quantitative Computed Tomography in Postmenopausal Women Treated with Bisphosphonates

2012 ◽  
Vol 39 (6) ◽  
pp. 1215-1220 ◽  
Author(s):  
SYMEON TOURNIS ◽  
VASILIOS SAMDANIS ◽  
SAVAS PSARELIS ◽  
CHRYSA LIAKOU ◽  
JULIA ANTONIOU ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Computed Tomography ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Quantitative Computed Tomography ◽  
Bone Geometry ◽  
Peripheral Quantitative Computed Tomography ◽  
Volumetric Bone Mineral Density ◽  
Mineral Density

Objective.To investigate the effect of rheumatoid arthritis (RA) on volumetric bone mineral density (vBMD) and bone geometry in postmenopausal women treated with bisphosphonates.Methods.Fifty-three postmenopausal women with RA and 87 control subjects, comparable in terms of age, body mass index, and years since menopause, underwent peripheral quantitative computed tomography (pQCT) of the nondominant tibia.Results.At 4% (trabecular site), trabecular bone mineral content (BMC) and vBMD (p < 0.001) were lower in the RA group, while trabecular area was comparable. At 38% (cortical site), cortical BMC (p < 0.01), area (p < 0.05), and thickness (p < 0.001) were lower in the RA group, whereas vBMD was comparable. Endosteal circumference was higher (p < 0.05), whereas periosteal circumference was comparable, indicating cancellization of cortical bone. In the RA group, muscle area was lower (p < 0.001), while at 14% polar stress strength index was significantly lower (p < 0.01) in patients with RA, indicating impairment of bone mechanical properties.Conclusion.RA is associated with negative effects on both cortical and cancellous bone in postmenopausal women treated with bisphosphonates. Cortical geometric properties are also adversely affected mainly by increased endosteal circumference, whereas trabecular geometric properties are generally preserved.

scholarly journals Pelvic floor disorder symptoms and bone strength in postmenopausal women

2020 ◽  
Vol 31 (9) ◽  
pp. 1777-1784
Author(s):  
Isuzu Meyer ◽  
Sarah L. Morgan ◽  
Alayne D. Markland ◽  
Jeff M. Szychowski ◽  
Holly E. Richter
Keyword(s):  
Pelvic Floor ◽  
Postmenopausal Women ◽  
Bone Strength ◽  
Pelvic Floor Disorder

scholarly journals Bone Density, Turnover, and Estimated Strength in Postmenopausal Women Treated With Odanacatib: A Randomized Trial

2013 ◽  
Vol 98 (2) ◽  
pp. 571-580 ◽  
Author(s):  
Kim Brixen ◽  
Roland Chapurlat ◽  
Angela M. Cheung ◽  
Tony M. Keaveny ◽  
Thomas Fuerst ◽  
...  
Keyword(s):  
Lumbar Spine ◽  
Bone Resorption ◽  
Bone Formation ◽  
Postmenopausal Women ◽  
Bone Strength ◽  
Bone Mineral ◽  
Bone Resorption Marker ◽  
Mineral Density ◽  
Volumetric Bmd ◽  
The Impact

Abstract Context: Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women with low BMD and cortical thickness in ovariectomized monkeys. Objective: The objective of the study was to examine the impact of odanacatib on the trabecular and cortical bone compartments and estimated strength at the hip and spine. Design: This was a randomized, double-blind, 2-year trial. Setting: The study was conducted at a private or institutional practice. Participants: Participants included 214 postmenopausal women with low areal BMD. Intervention: The intervention included odanacatib 50 mg or placebo weekly. Main Outcome Measures: Changes in areal BMD by dual-energy x-ray absorptiometry (primary end point, 1 year areal BMD change at lumbar spine), bone turnover markers, volumetric BMD by quantitative computed tomography (QCT), and bone strength estimated by finite element analysis were measured. Results: Year 1 lumbar spine areal BMD percent change from baseline was 3.5% greater with odanacatib than placebo (P &lt; .001). Bone-resorption marker C-telopeptide of type 1 collagen was significantly lower with odanacatib vs placebo at 6 months and 2 years (P &lt; .001). Bone-formation marker procollagen I N-terminal peptide initially decreased with odanacatib but by 2 years did not differ from placebo. After 6 months, odanacatib-treated women had greater increases in trabecular volumetric BMD and estimated compressive strength at the spine and integral and trabecular volumetric BMD and estimated strength at the hip (P &lt; .001). At the cortical envelope of the femoral neck, bone mineral content, thickness, volume, and cross-sectional area also increased from baseline with odanacatib vs placebo (P &lt; .001 at 24 months). Adverse experiences were similar between groups. Conclusions: Over 2 years, odanacatib decreased bone resorption, maintained bone formation, increased areal and volumetric BMD, and increased estimated bone strength at both the hip and spine.

Sign in / Sign up

Export Citation Format

Share Document